CN102595894A - 治疗疟疾和预防疟疾传播的化合物 - Google Patents

治疗疟疾和预防疟疾传播的化合物 Download PDF

Info

Publication number
CN102595894A
CN102595894A CN2010800380710A CN201080038071A CN102595894A CN 102595894 A CN102595894 A CN 102595894A CN 2010800380710 A CN2010800380710 A CN 2010800380710A CN 201080038071 A CN201080038071 A CN 201080038071A CN 102595894 A CN102595894 A CN 102595894A
Authority
CN
China
Prior art keywords
compound
compounds
malaria
inhibitors
rings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800380710A
Other languages
English (en)
Chinese (zh)
Inventor
苏新传
苑京
迪帕克·拉杰
西蒂波恩·帕塔拉蒂洛克拉特
兰·约翰逊
黄瑞丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN102595894A publication Critical patent/CN102595894A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
CN2010800380710A 2009-08-27 2010-08-27 治疗疟疾和预防疟疾传播的化合物 Pending CN102595894A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23741709P 2009-08-27 2009-08-27
US61/237,417 2009-08-27
PCT/US2010/047019 WO2011025969A1 (en) 2009-08-27 2010-08-27 Compounds that treat malaria and prevent malaria transmission

Publications (1)

Publication Number Publication Date
CN102595894A true CN102595894A (zh) 2012-07-18

Family

ID=43628406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800380710A Pending CN102595894A (zh) 2009-08-27 2010-08-27 治疗疟疾和预防疟疾传播的化合物

Country Status (6)

Country Link
US (2) US9375424B2 (enExample)
EP (1) EP2470013A4 (enExample)
CN (1) CN102595894A (enExample)
CA (1) CA2772085A1 (enExample)
IN (1) IN2012DN01684A (enExample)
WO (1) WO2011025969A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017050297A1 (en) * 2015-09-25 2017-03-30 Sun Jet Biotechnology Inc. Combination therapy for ev71 infection
CN109312363A (zh) * 2018-04-26 2019-02-05 广州中科蓝华生物科技有限公司 一种减毒系统及其应用
CN116987040A (zh) * 2023-06-21 2023-11-03 中国中医科学院中药研究所 二苯并二氮杂卓衍生物及其制备方法和应用
CN117064888A (zh) * 2023-09-26 2023-11-17 中国科学院水生生物研究所 氯喹或其药学上可接受的盐在制备预防生产非整倍体配子的药物中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
WO2013082469A2 (en) * 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
WO2014031872A2 (en) * 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
WO2014113495A1 (en) 2013-01-15 2014-07-24 The Trustees Of Columbia University In The City Of New York Activation or reactivation of ache
EP3416972A1 (en) 2016-02-19 2018-12-26 Council of Scientific & Industrial Research Silicon based cyclic compounds and pharmaceutical compositions for treating malaria and toxoplasmosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011757A2 (en) * 2000-08-08 2002-02-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for inhibiting transmission of malaria

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5373005A (en) * 1988-04-20 1994-12-13 Merrell Dow Pharmaceuticals Inc. Despiramine in the treatment of drug-resistant malarial infections
US5853739A (en) * 1988-05-02 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Transmission-blocking vaccine against malaria
DE3821392A1 (de) * 1988-06-24 1989-12-28 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on (ebselen)
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
AU691306B2 (en) * 1994-06-17 1998-05-14 F. Hoffmann-La Roche Ag N,n'-bis(quinolin-4-yl)-diamine derivatives, their preparation and their use as antimalarials
JP2002541144A (ja) * 1999-01-26 2002-12-03 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 医薬的に活性のある化合物及びその使用方法
US6881841B2 (en) * 2000-11-22 2005-04-19 Tsutomu Takeuchi Dibenzosuberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives
US7670631B2 (en) * 2003-03-12 2010-03-02 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
DE10353186A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
TW200615273A (en) * 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
WO2008064011A1 (en) * 2006-11-13 2008-05-29 The Government Of The U.S. Of America As Represented By The Department Of Veterans Affairs Acridone compounds
WO2009026858A1 (es) * 2007-08-28 2009-03-05 Centro De Quimica Farmaceutica Derivados de la acridinona como agentes antiparasitarios, antifungicos y antivirales.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011757A2 (en) * 2000-08-08 2002-02-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for inhibiting transmission of malaria

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NARESH SINGH, S.K. PURI: "Causal prophylactic activity of antihistaminic agents against Plasmodium yoelii nigeriensis infection in Swiss mice", 《ACTA TROPICA》 *
黄文洲等: "酮替芬治疗猴疟的研究", 《药学学报》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017050297A1 (en) * 2015-09-25 2017-03-30 Sun Jet Biotechnology Inc. Combination therapy for ev71 infection
US10548915B2 (en) 2015-09-25 2020-02-04 Sun Jet Biotechnology Inc. Combination therapy for EV71 infection
CN109312363A (zh) * 2018-04-26 2019-02-05 广州中科蓝华生物科技有限公司 一种减毒系统及其应用
CN109312363B (zh) * 2018-04-26 2022-07-15 中科蓝华(广州)生物医药技术有限公司 一种减毒系统及其应用
US11524060B2 (en) 2018-04-26 2022-12-13 Guangzhou Cas Lamvac Biotech Co., Ltd Attenuation system and use thereof
CN116987040A (zh) * 2023-06-21 2023-11-03 中国中医科学院中药研究所 二苯并二氮杂卓衍生物及其制备方法和应用
CN116987040B (zh) * 2023-06-21 2025-09-23 中国中医科学院中药研究所 二苯并二氮杂卓衍生物及其制备方法和应用
CN117064888A (zh) * 2023-09-26 2023-11-17 中国科学院水生生物研究所 氯喹或其药学上可接受的盐在制备预防生产非整倍体配子的药物中的应用

Also Published As

Publication number Publication date
US9375424B2 (en) 2016-06-28
US20160303103A1 (en) 2016-10-20
US20120196882A1 (en) 2012-08-02
IN2012DN01684A (enExample) 2015-06-05
WO2011025969A1 (en) 2011-03-03
EP2470013A4 (en) 2013-05-01
CA2772085A1 (en) 2011-03-03
EP2470013A1 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
CN102595894A (zh) 治疗疟疾和预防疟疾传播的化合物
Vangapandu et al. Recent advances in antimalarial drug development
RU2560676C2 (ru) Противотуберкулезная композиция, содержащая соединения оксазола
US9493420B2 (en) Quinoline derivatives and uses thereof
AU2009313906A1 (en) Treatment of proteinopathies using a farnesyl transferase inhibitor
TWI387456B (zh) 用於治療瘧疾之二茂鐵氯奎（ｆｅｒｒｏｑｕｉｎｅ）及黃花蒿素（ａｒｔｅｍｉｓｉｎｉｎ）衍生物之組合
Shapiro et al. Chemotherapy of protozoal infections
US20140163013A1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
US20050288298A1 (en) Methods for the treatment of synucleinopathies
US11491162B2 (en) Combination of quinoline-4-carboxamides and benzonaphthyridine derivatives as antimalarial drug combination
WO2017143964A1 (zh) Quisinostat，一种新型的高效抗疟药物
US20100317666A1 (en) Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss
NZ587232A (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
EP2520297A1 (en) Rubreserine and its derivates with antiparasitic activity
JPH08231401A (ja) マラリアの予防または治療薬
JP7565603B2 (ja) マラリア原虫の増殖抑制剤
Dassonville-Klimpt et al. Mefloquine derivatives: synthesis, mechanisms of action, antimicrobial activities
US20100292472A1 (en) Prophylactic and therapeutic medicine for malaria
US11485714B2 (en) Hydroxyethylamine-based piperazine compounds, and methods of producing and using the same for treating disease
EP4069232B1 (en) Masupirdine for treating behavioral and psychological symptoms in dementia
KR101701547B1 (ko) 말라리아의 치료 또는 예방에 있어서의 페로퀸의 용도
US20220332685A1 (en) Compound derived from quinoline, use of a compound, composition and method for the treatment or prophylaxis of a condition caused by a blood parasite
US10550135B2 (en) Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity
US20220409614A1 (en) Treating behavioral and psychological symptoms in dementia patients
Ashley et al. 19 Antimalarial Agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20120718

RJ01 Rejection of invention patent application after publication